Inicio › Cáncer de ovario › Minnesota › Rochester
Ensayos clínicos de Cáncer de ovario en Rochester, MN
29 estudios para Cáncer de ovario buscan participantes en centros de Rochester y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
ReclutandoFase 2/3
- Mayo Clinic in Rochester, Rochester
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
ReclutandoFase 2
- Mayo Clinic in Rochester, Rochester
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
ReclutandoEstudio observacional
- Mayo Clinic, Rochester
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Reclutando
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
ReclutandoEstudio observacional
- Mayo Clinic Rochester, Rochester
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
ReclutandoFase 1/2
- Mayo Clinic - Rochester, Rochester
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
ReclutandoFase 3
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
ReclutandoFase 1
- Mayo Clinic - Rochester, Rochester
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
ReclutandoFase 1/2
- Mayo Rochester, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
ReclutandoEstudio observacional
- Mayo Clinic (Rochester), Rochester
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Reclutando
- Mayo Clinic in Rochester, Rochester
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
ReclutandoFase 3
- Mayo Clinic in Rochester, Rochester
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
ReclutandoFase 1/2
- Mayo Clinic (Minnesota), Rochester
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
ReclutandoFase 3
- Mayo Clinic Methodist Campus, Rochester
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
ReclutandoFase 2
- Mayo Clinic, Rochester
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
ReclutandoFase 1/2
- The Mayo Clinic, Rochester
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
ReclutandoFase 1
- Mayo Clinic, Rochester
Lead-212 PSV359 Therapy for Patients With Solid Tumors
ReclutandoFase 1/2
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
ReclutandoFase 1/2
- Mayo Clinic - Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
ReclutandoFase 1/2
- Mayo Clinic Rochester, Rochester
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
Reclutando
- Mayo Clinic, Rochester
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
ReclutandoFase 3
- Mayo Clinic, Rochester
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Reclutando
- Mayo Clinic, Rochester
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
ReclutandoFase 1/2
- Mayo Clinic, Rochester
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
ReclutandoFase 1
- Mayo Clinic in Rochester, Rochester
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
Reclutando
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Mayo Clinic, Rochester
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
ReclutandoFase 2
- Mayo Clinic, Rochester
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
ReclutandoFase 1
- Exelixis Clinical Site #14, Rochester
Más información sobre Cáncer de ovario en MedlinePlus
Ensayos de Cáncer de ovario en otras ciudades
- Houston, TX89 estudios
- New York City, NY69 estudios
- Boston, MA61 estudios
- Los Angeles, CA50 estudios
- Nashville, TN49 estudios
- Arlington, VA46 estudios
- Philadelphia, PA44 estudios
- Columbus, OH39 estudios
- St. Louis, MO38 estudios
- Chicago, IL36 estudios
- San Antonio, TX31 estudios
- Cleveland, OH30 estudios
Otros estudios en Rochester
- Cáncer de seno42 estudios
- Cáncer de pulmón de células no pequeñas37 estudios
- Cáncer metastásico31 estudios
- Cáncer (todos los tipos)30 estudios
- Cáncer del colon y del recto29 estudios
- Mieloma múltiple24 estudios
- Fallo cardíaco22 estudios
- Cáncer de próstata22 estudios
- Cáncer de páncreas22 estudios
- Cáncer de endometrio20 estudios
- Cáncer de pulmón20 estudios
- Leucemia linfocítica crónica18 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.